Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043394 · ClinicalTrials.gov registry record · Phase 2
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00043394 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT00043394, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Interventions
- DRUG Herceptin®
- DRUG 0.04 mg/kg CpG 7909
- DRUG 0.08 mg/kg CpG 7909
- DRUG 0.12 mg/kg CpG 7909
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043394
The ClinicalTrials.gov registry entry for NCT00043394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Herceptin® is the first listed.
NCT00043394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043394 about?
NCT00043394 is a clinical study titled "CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer". To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
What is the current status of trial NCT00043394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2002-09. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00043394?
The interventions under investigation include: Herceptin® (DRUG), 0.04 mg/kg CpG 7909 (DRUG), 0.08 mg/kg CpG 7909 (DRUG), 0.12 mg/kg CpG 7909 (DRUG).
Who is sponsoring clinical trial NCT00043394?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.